They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

Novo Nordisk is advancing its research into obesity treatments by launching new trials for its experimental drug, CagriSema. This decision follows market disappointment after previous trial results.

The Novo Nordisk class action lawsuit further alleges that on December 20, 2024, defendants published headline results from their REDEFINE-1 CagriSema obesity trial, disclosing that "[t]he ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

However, not all news has been positive. Novo Nordisk faced setbacks with its CagriSema obesity treatment, as the results from the REDEFINE-1 trial were disappointing, showing lower-than-expected ...